|Bid||4.22 x 800|
|Ask||4.43 x 3000|
|Day's Range||4.38 - 4.84|
|52 Week Range||2.02 - 5.82|
|Beta (3Y Monthly)||3.30|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The latest enhancements in Pacific Biosciences??? (PACB) Sequel System represent strong improvement in terms of read length, throughput and accuracy in DNA sequencing.
Pacific Biosciences (PACB) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.
Today, Pacific Biosciences of California (PACB) is trading at $5.16 per share, up ~6.17% from yesterday’s close of $4.86. On September 12, Pacific Biosciences stock closed at $4.86, a 6.46% increase from its September 11 closing price of $4.57. Its September 12 stock price represented an ~141.0% rise from its 52-week low of $2.02 on April 2. Its stock price hit its 52-week high of $5.58 on October 3, 2017.
Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.
Investors are always looking for growth in small-cap stocks like Pacific Biosciences of California Inc (NASDAQ:PACB), with a market cap of US$658.4m. However, an important fact which most ignore is:Read More...
Pacific Biosciences thinks platform upgrades will cut its Sequel machines' DNA sequencing costs 92% by 2019, opening a $2.5 billion market opportunity in 2022.
Shipments delayed in the first quarter were installed in the second quarter, boosting the gene-sequencing company's revenue.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 2) Akcea Therapeutics Inc (NASDAQ: AKCA ) Arbutus Biopharma Corp ...
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0.00% and -8.72%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Menlo Park, California-based company said it had a loss of 17 cents. The results matched Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Pacific Biosciences of California, Inc. (PACB) is looking like an interesting pick from a technical perspective
For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Pacific Biosciences of California Inc’s (NASDAQ:PACB) track record on a highRead More...
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.